Unexplained weight loss (UWL), characterized by a decrease in body weight without an intentional effort, is a phenomenon that often presents a diagnostic challenge in clinical practice. This article aims to provide a comprehensive approach to the evaluation of UWL, highlighting the importance of a thorough assessment, differential diagnosis, and evidence-based management strategies.
The initial assessment should involve a detailed medical history, focusing on dietary habits, physical activity, medication use, and psychosocial factors. A comprehensive physical examination should also be conducted to identify potential signs of systemic diseases. It is essential to quantify the weight loss and assess whether it is clinically significant, typically defined as a loss of more than 5% of body weight over a period of 6-12 months.
UWL can be a manifestation of various underlying conditions, ranging from malignancies and gastrointestinal diseases to endocrine disorders and psychiatric illnesses. Therefore, a broad differential diagnosis is crucial. Clinicians should consider age, associated symptoms, and risk factors to guide the diagnostic process. Laboratory investigations and imaging studies may be warranted based on clinical suspicion.
Management should be tailored to the identified cause of UWL. In cases where no clear etiology is found, a symptom-based approach may be adopted. Nutritional support and regular monitoring are fundamental in all cases. It is also important to consider the psychological impact of UWL and provide appropriate support.
Unexplained weight loss remains a complex clinical issue that requires a comprehensive, patient-centered approach. Understanding the potential causes and adopting a systematic evaluation strategy are key to ensuring optimal patient outcomes. Continuous research is needed to further improve our understanding and management of this challenging clinical scenario.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation